Comparing Zura Bio (NASDAQ:ZURA) & Creative Medical Technology (NASDAQ:CELZ)

Zura Bio (NASDAQ:ZURA) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Zura Bio and Creative Medical Technology, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	0	0	4	1	3.20
Creative Medical Technology	0	0	0	0	N/A

Zura Bio presently has a consensus target price of $16.40, suggesting a potential upside of 344.44%. Given Zura Bio’s higher possible upside, equities analysts clearly believe Zura Bio is more favorable than Creative Medical Technology.

Valuation & Earnings

This table compares Zura Bio and Creative Medical Technology’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$69.24 million	N/A	N/A
Creative Medical Technology	$10,000.00	654.16	-$5.29 million	($3.71)	-1.30

Creative Medical Technology has higher revenue and earnings than Zura Bio.

Volatility & Risk

Zura Bio has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Creative Medical Technology has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500.

Institutional and Insider Ownership

61.1% of Zura Bio shares are held by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are held by institutional investors. 15.8% of Zura Bio shares are held by company insiders. Comparatively, 3.3% of Creative Medical Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Zura Bio and Creative Medical Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-82.30%	-66.71%
Creative Medical Technology	N/A	-41.48%	-40.22%

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.